This statistic depicts the top ten pharmaceutical companies worldwide based on the global anti-diabetic revenue market share in 2017 and a projection for 2024. In 2017, Merck & Co accounted for some 12.8 percent of the global market for anti-diabetics, and is expected to decrease to some 5.3 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.

The Report Covers the Global Diabetes Drug Market Outlook and Trends. The Market is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drugs, and Combination Drugs), by Route of Administration (Oral, Intravenous, Subcutaneous), by Distribution Channel (Online, and Offline), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The Report Provided the Value in (USD) and Volume (Ml) for the Above Segments.

The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.

The Report Covers United States Diabetes Care Drugs Market Companies and It is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-insulin Injectable Drugs, And Combination Drugs). The Report Offers the Value (in USD) and Volume (in Unit) for the Above Segments.

The Report Covers Europe Diabetes Drugs Companies and It is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, and Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sglt-2 Inhibitors, Dpp-4 Inhibitors, Sulfonylureas, and Meglitinides), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), and Combination Drugs (insulin Combinations and Oral Combinations)) and Geography (United Kingdom, Germany, Italy, Spain, France, Russia, and the Rest of Europe). The Report Offers the Value (in USD) for the Above Segments.

The global obesity-diabetes drugs market is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.

Country-wise Insights

Category-Wise Insights

This statistic displays the market share of top anti-diabetic products worldwide in 2017 and a projection for 2024. Novo Nordisk's Ozempic is expected to have a market share of 7.4 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.

According to the forecasts, Trulicity, an injectable diabetes medication manufactured by pharmaceutical company Eli Lilly, will have the highest sales in both 2020 and 2024 as they are estimated to reach 4.8 billion U.S. dollars and 6.6 billion U.S. dollars, respectively.

The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, And Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The U.S. Diabetes Drug Market is projected to grow USD 40.32 billion by 2033, segmented by type, delivery method, drug class, distribution channel, and region.

Discover the Saudi Arabia Diabetes Drug Market, valued at USD 2 billion in 2024, is projected to reach USD 3.4 billion by 2030, growing at a CAGR of 9%.

Concerning the 11 selected segments, the segment Other has the largest value share by brand with 56 percent. Contrastingly, Tresiba is ranked last, with two percent. Their difference, compared to Other, lies at 54 percentage points. The Statista Market Insights cover a broad range of additional markets.

The global pediatric diabetes therapeutic market is set to reach USD 1,633.8 million in 2024. Projections indicate that the sector is anticipated to elevate to USD 2,612.4 million by 2034. The industry stood at USD 1,540.2 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 6.1% in 2024. Demand for pediatric diabetes therapeutics is slated to surge at a 4.8% CAGR.

Country-wise Insights

Category-wise Insights

The Report Covers North America Diabetes Drug Manufacturers and It is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, and Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, and Meglitinides), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), and Combination Drugs (insulin Combinations and Oral Combinations)) and Geography (United States, Canada, and Rest of North America). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Diabetes Nutrition Market is growing at a CAGR of 6.50% over the next 7 years. Nestle, Fresenius Kabi AG, Abbott, Danone S.A., Zemaica Healthcare and many more major companies operating in this Market.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

The pet diabetes care devices market is capturing a valuation of US$ 2.3 billion in 2023 and is expected to reach US$ 4.3 billion by 2033. The market is registering a CAGR of 6.2% during the forecast period.

Scope of Report

The global diabetic food market size reached USD 12.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 23.3 Billion by 2033, exhibiting a growth rate (CAGR) of 6.47% during 2025-2033. The market is growing rapidly driven by increasing prevalence of diabetes, heightened awareness about health and nutrition among consumers, recent advancements in food technologies, imposition of various initiatives and regulations by governments, and changing lifestyle patterns of consumers.

In December 2023, the Danish pharmaceutical company Novo Nordisk controlled more than half of the insulin market in China, in terms of sales volume. Founded in 1923, the firm specializes in producing diabetes medications, which accounted for around 80 percent of its annual sales revenue in 2023.

This statistic depicts the market share of the global top diabetes care devices manufacturers in 2011. In that year, Medtronic from the United States had a 7.5 percent share in the total global market for diabetes care devices.

Top diabetes care devices manufacturers

Diabetes is one of the leading causes of death in the United States. In 2010, 20.8 people per 100,000 of the U.S. population died due to diabetes. In the United States, 239 billion U.S. dollars was expended in 2013 to treat diabetes. However, in China, a country with one of the largest number of diabetics in the world, only 38 billion U.S. dollars was spent on diabetes health care. The diabetes care market is expected to grow to almost 16 billion U.S. dollars in the United States by 2017.

In 2011, F.Hoffman-La Roche Ltd and LifeScan, Inc. together are considered a large part of the top diabetes care device manufacturers in the world at 15.2 percent and 14.2 percent of the global market share, respectively. Lifescan is part of the Johnson & Johnson Company and has developed glucose monitoring devices such as OneTouch Ultra for home and hospital use. About 61 percent of global diabetes care devices can be listed under the glucose monitoring device category and 24 percent under insulin delivery devices. Insulin pump therapy has vastly improved since the 1970s, with alarms for malfunction and wireless connection to meters and computers. This type of device is a widely used product for diabetics around the world.